English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18055/20253 (89%)
Visitors : 44111      Online Users : 408
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34144


    標題: Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy
    作者: Yeh, Ming-Lun
    Kuo, Hsing-Tao
    Huang, Ching-, I
    Huang, Chung-Feng
    Hsieh, Ming-Yen
    Liang, Po-Cheng
    Lin, I-Hung
    Hsieh, Meng-Hsuan
    Lin, Zu-Yau
    Chen, Shinn-Chern
    Dai, Chia-Yen
    Huang, Jee-Fu
    Yu, Ming-Lung
    Chuang, Wan-Long
    貢獻者: Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div
    Kaohsiung Med Univ, Coll Med, Fac Med
    Kaohsiung Med Univ, Coll Med, Hepatitis Res Ctr
    Kaohsiung Med Univ, Canc Res Ctr
    Kaohsiung Med Univ, Ctr Liquid Biopsy
    Chi Mei Med Ctr, Dept Internal Med, Div Hepatogastroenterol
    Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management
    Natl Sun Yat Sen Univ, Inst Biomed Sci
    Natl Chiao Tung Univ, Coll Biol Sci & Technol
    關鍵字: direct acting antivirals
    hepatitis C virus
    hepatocellular carcinoma
    Sorafenib
    survival
    日期: 2021
    上傳時間: 2022-11-18 11:25:50 (UTC+8)
    出版者: Wiley
    摘要: Whether patients with advanced hepatocellular carcinoma (aHCC) benefit from hepatitis C virus (HCV) eradication is uncertain. We aimed to investigate whether a survival benefit was conferred by HCV eradication in aHCC patients. This retrospective cohort study enrolled 168 HCV-infected aHCC patients from April 2013 to January 2019. All patients were treated with sorafenib. Endpoints included overall survival (OS), progression free survival (PFS), and time to liver decompensation. Patients with undetectable HCV RNA exhibited reduced aspartate aminotransferase and alpha fetoprotein levels, as well as an attenuated proportion of aHCC at initial diagnosis but increased albumin and mean sorafenib daily dosing. Patients with undetectable HCV RNA exhibited significantly longer OS compared to patients with detectable or unknown HCV RNA, which was an independent factor of OS (HR: 0.56, 95% CI: 0.350-0.903,P= .017). Patients with undetectable HCV RNA also presented a trend for longer PFS (HR 0.68, 95% CI: 0.46-1.00,P= .053). The survival benefit was considered with respect to the significantly prolonged time to Child-Pugh B scores in patients with undetectable HCV RNA (HR 0.59, 95% CI: 0.38-0.92,P= .020). Patients with detectable HCV RNA at sorafenib initiation who further received direct acting antiviral therapy also had significantly longer OS (HR 0.11, 95% CI: 0.02-0.81,P= .030) and PFS (HR 0.23, 95% CI: 0.06-0.99,P= .048). In conclusion, abolishing HCV viremia preserves liver function and confers a survival benefit in advanced HCC patients on sorafenib treatment.
    關聯: Kaohsiung Journal of Medical Sciences, v.37, n.2, pp.9
    Appears in Collections:[高齡福祉養生管理系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML366View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback